Enanta Pharmaceuticals (ENTA) Reaches $35.74 After 9.00% Up Move, Cti Industries (CTIB) Has 0.33 Sentiment

July 11, 2017 - By Winifred Garcia

CTI Industries Corporation develops, produces and distributes various consumer products and sells these products throughout the United States and in over 35 other countries. The company has market cap of $21.71 million. The Firm designs, makes and distributes film products. It has a 38.19 P/E ratio. It is a developer of products, which employ flexible films, including balloons, pouches and rolls of film for vacuum sealing and storage of products in the home and films for commercial packaging applications.

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! About 151,091 shares traded. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since July 11, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.The move comes after 6 months positive chart setup for the $638.31 million company. It was reported on Jul, 11 by Barchart.com. We have $38.96 PT which if reached, will make NASDAQ:ENTA worth $57.45M more.

Investors sentiment decreased to 1.47 in 2016 Q4. Its down 0.06, from 1.53 in 2016Q3. It is negative, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported. Blackrock Mngmt Ltd Liability Corporation has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Prelude Capital Mngmt Limited Liability Company holds 6,002 shares. Alps Advsr has invested 0.01% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Art Advisors Limited Liability Co holds 0.02% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) or 8,000 shares. Tiaa Cref Inv Lc holds 0% or 47,591 shares. Metropolitan Life Insur Ny holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 11,660 shares. State Of Tennessee Treasury Department, Tennessee-based fund reported 10,446 shares. Proshare Advisors Limited Liability Co reported 0.01% stake. Airain Limited invested 0.02% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Financial Bank Of America De reported 0% stake. Nationwide Fund Advisors holds 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) or 11,925 shares. Gotham Asset Management Limited Liability invested in 50,629 shares or 0.02% of the stock. Granahan Mngmt Inc Ma stated it has 496,025 shares or 0.57% of all its holdings. Acadian Asset Management Ltd has invested 0.09% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Assetmark Inc invested in 0% or 13 shares.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $638.31 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Among 4 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Enanta Pharmaceuticals Inc had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Underweight” rating given on Friday, October 23 by Barclays Capital. JMP Securities upgraded the shares of ENTA in report on Friday, October 23 to “Mkt Outperform” rating. The stock has “Buy” rating by TheStreet on Saturday, August 8. The firm has “Buy” rating given on Friday, August 7 by Zacks. The company was upgraded on Tuesday, July 11 by JMP Securities. As per Thursday, April 28, the company rating was downgraded by JMP Securities. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 9.